An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma

Trial Profile

An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Ibrutinib (Primary) ; Lenalidomide; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2018 Planned number of patients changed from 60 to 56.
    • 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 09 Feb 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top